Clinical Trials Using Anti-CD47 Monoclonal Antibody Hu5F9-G4
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD47 Monoclonal Antibody Hu5F9-G4. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
This trial will evaluate magrolimab, a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the cancer cells. In this study, magrolimab may be given alone or in combination with azacitidine to patients with acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS). Azacitidine is a drug used for treatment of AML or MDS in patients who are not eligible for typical chemotherapy. The major aims of the study are: to confirm the safety and tolerability of magrolimab monotherapy in a relapsed / refractory AML and MDS population, and of magrolimab in combination with azacitidine in previously untreated AML and MDS; to evaluate the efficacy of magrolimab monotherapy in relapsed / refractory AML / MDS, and of magrolimab in combination with azacitidine in previously untreated AML / MDS, as measured by the objective response rate; and to evaluate the safety, tolerability, and efficacy of magrolimab monotherapy or combination with azacitidine in low-risk MDS patients as measured by RBC transfusion independence rate.
Location: 19 locations
Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed / Refractory B-cell Non-Hodgkin's Lymphoma
This Phase 1b / 2 trial will evaluate Hu5F9-G4 (magrolimab) in combination with rituximab and magrolimab or in combination with R-GemOx. Magrolimab is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the cancer cells. Rituximab is a monoclonal antibody drug that is used for treatment of non-Hodgkin's lymphoma and other types of cancer. Gemcitabine and Oxaliplatin are chemotherapy commonly used with rituximab in treating NHL. The major aims of the trial are: (Phase 1b) to investigate the safety and tolerability of sequential dose cohorts and to determine a recommended Phase 2 dose for Hu5F9-G4 in combination with rituximab, and (Phase 2) to evaluate the efficacy of Hu5F9-G4 in combination with rituximab in patients with indolent lymphoma or diffuse large B-cell lymphoma as measured by the overall response rate.
Location: 14 locations
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed / refractory aggressive Non-Hodgkin's Lymphoma (NHL).
Location: 4 locations
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate / high / very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and duration of CR.
Location: 9 locations
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
A Phase Ib / II, open-label, multicenter, randomized, umbrella study in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status).
Location: 2 locations
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
This phase Ib / II trial studies the side effects and best dose of magrolimab and venetoclax when given together with azacitidine and to see how well they work in treating patients with acute myeloid leukemia. Chemotherapy drugs, such as venetoclax and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Magrolimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving magrolimab, azacitidine, and venetoclax may help to control the disease.
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned after or Does Not Respond to Treatment
This phase Ib / II trial investigates the side effects and best dose of magrolimab when given together with mogamulizumab and to see how well it works in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome that has come back (relapsed) or does not respond to treatment (refractory). Magrolimab and mogamulizumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread.
Location: Location information is not yet available.